Vontobel Holding Ltd. Has $2.04 Million Position in BioNTech SE (NASDAQ:BNTX)

Vontobel Holding Ltd. lessened its position in BioNTech SE (NASDAQ:BNTX) by 62.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 17,158 shares of the company’s stock after selling 28,574 shares during the quarter. Vontobel Holding Ltd.’s holdings in BioNTech were worth $2,038,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of BNTX. Candriam S.C.A. boosted its stake in shares of BioNTech by 261.2% during the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after buying an additional 418,695 shares during the last quarter. Point72 Asset Management L.P. boosted its position in BioNTech by 283.5% during the second quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock valued at $37,103,000 after purchasing an additional 341,311 shares during the last quarter. SG Americas Securities LLC grew its stake in BioNTech by 610.5% in the first quarter. SG Americas Securities LLC now owns 70,143 shares of the company’s stock valued at $6,471,000 after purchasing an additional 60,270 shares in the last quarter. Acadian Asset Management LLC increased its position in shares of BioNTech by 51.3% during the 1st quarter. Acadian Asset Management LLC now owns 111,398 shares of the company’s stock worth $10,275,000 after purchasing an additional 37,792 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of BioNTech during the 2nd quarter worth approximately $2,892,000. Institutional investors own 15.52% of the company’s stock.

BioNTech Trading Down 2.4 %

BNTX stock opened at $111.77 on Friday. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49. The company has a market capitalization of $26.57 billion, a PE ratio of 223.54 and a beta of 0.24. The company’s 50-day simple moving average is $104.56 and its 200 day simple moving average is $94.20. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.40 and a current ratio of 7.54.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The business had revenue of $128.70 million for the quarter, compared to analyst estimates of $134.98 million. During the same quarter in the previous year, the company earned ($0.86) EPS. The business’s revenue for the quarter was down 23.3% on a year-over-year basis. As a group, sell-side analysts anticipate that BioNTech SE will post -3.04 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. JPMorgan Chase & Co. raised shares of BioNTech from an “underweight” rating to a “neutral” rating and raised their target price for the company from $91.00 to $125.00 in a research note on Monday, September 16th. TD Cowen lowered their price objective on shares of BioNTech from $98.00 to $85.00 and set a “hold” rating on the stock in a research note on Tuesday, August 6th. HC Wainwright upped their target price on shares of BioNTech from $113.00 to $150.00 and gave the company a “buy” rating in a report on Monday, October 7th. Deutsche Bank Aktiengesellschaft lifted their price target on BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, September 19th. Finally, UBS Group raised their price objective on BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a research report on Wednesday, September 18th. Five equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, BioNTech has a consensus rating of “Moderate Buy” and a consensus target price of $131.92.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.